Ignite Creation Date:
2025-12-24 @ 4:08 PM
Ignite Modification Date:
2026-01-10 @ 2:02 PM
Study NCT ID:
NCT00645866
Status:
COMPLETED
Last Update Posted:
2011-05-16
First Post:
2008-03-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-04
Start Date Type:
None
Primary Completion Date:
2006-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2006-03
Completion Date Type:
ACTUAL
First Submit Date:
2008-03-27
First Submit QC Date:
None
Study First Post Date:
2008-03-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-05-13
Last Update Post Date:
2011-05-16
Last Update Post Date Type:
ESTIMATED